GREENLAND MINES LTD Sale of Stock, Consideration Received on Transaction
GREENLAND MINES LTD (GRML) reported Sale of Stock, Consideration Received on Transaction of $46.10 thousand for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-17.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-08-17
- GREENLAND MINES LTD sale of stock, consideration received on transaction for the quarter ending 2025-06-30 was $0.00.
- GREENLAND MINES LTD sale of stock, consideration received on transaction for the quarter ending 2025-03-31 was $46.10K.
- GREENLAND MINES LTD sale of stock, consideration received on transaction for fiscal 2024 was $985.37K.
| Period end | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|---|---|
| 2025-12-31 | $46.10K 10-Q · filed 2026-08-17 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-K/A 3 month · filed 2026-08-17 | $46.10K 10-Q · filed 2026-08-17 | |
| 2025-03-31 | $46.10K 10-K/A · filed 2026-08-14 | ||
| 2024-12-31 | $985.37K 10-K · filed 2025-03-31 | ||
| 2024-06-30 | $60.00M 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |